Press Releases

Atomwise SAB, BOD 2021
Atomwise Adds Pharma Luminaries to Board of Directors and Scientific Advisory Board

Experts include Mike Varney, Bruce Roth, John Hamer, Kemal Malik, and Andrew Lo SAN FRANCISCO, Calif., June 17, 2021 – Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on […]


June 17, 2021
Atomwise Named to the 2020 CB Insights Digital Health 150 — List of Most Innovative Digital Health Startups

Atomwise recognized for achievements in AI-driven drug discovery and creation of the AtomNet® platform, which has tackled — and succeeded in — finding small molecule hits for more undruggable targets than any other platform NEW YORK, August 13, 2020 — CB Insights today named Atomwise to its second annual Digital Health 150 ranking, which showcases […]


August 13, 2020
Atomwise Announces Largest China-US Collaboration for AI Drug Discovery

Atomwise could receive up to US$1.5 billion to develop first in-class and best in-class small molecules through partnership with China’s leading biopharmaceutical company, Hansoh Pharma.

Atomwise and Atropos Launch Joint Venture to Discover Senescence Modulating Small Molecules for Cancer Patients

Atomwise and Atropos Therapeutics form a joint venture to discover and develop anticancer agents using senescence assay and AI technologies.

SEngine Precision Medicine and Atomwise Announce Strategic Joint Venture to Accelerate Novel Drug Discovery

Joint venture brings together AI technology and living tumor organoids to develop novel personalized therapies for cancer patients SEATTLE, Wash., and SAN FRANCISCO, Calif. – SEngine Precision Medicine and Atomwise, Inc. today announced a joint venture to accelerate novel oncology drug discovery utilizing the unique platform technologies each company has validated through years of development. […]

Research collaboration between U-M and Atomwise to accelerate drug discovery using innovative Artificial Intelligence approach

Ann Arbor, Michigan – From making pain management safer and more effective to identifying inhibitors for a fibrosis target protein and more, researchers from Michigan Medicine, as well as the University of Michigan College of Pharmacy and U-M Life Sciences Institute, are looking to advance their projects through Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards […]

Atomwise Announces Multi-year, Multi-target Agreement with Lilly for AI-Driven Drug Discovery Program

Atomwise Inc. today announced a multi-year agreement with Eli Lilly and Company to apply Atomwise’s patented artificial intelligence (AI) technology in support of Lilly’s preclinical drug discovery efforts. The companies will collaborate on up to ten drug targets selected by Lilly, with the goal of accelerating the time it takes to identify and develop potential […]